Dr. Walid L. Shaib, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 297
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
GA license 068617
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Wellstar Kennestone Regional Medical Center Marietta, GA
- Wellstar Cobb Medical Center Austell, GA
- Wellstar PAulding Medical Center Hiram, GA
- Wellstar North Fulton Medical Center Roswell, GA
- Piedmont Cartersville Medical Center Cartersville, GA
Medical groups
- Wellstar Medical Group LLC (3,093 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 297
- Services billed
- 1,255
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 484 | 215 |
| Established patient office or other outpatient visit, 40-54 minutes | 213 | 79 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 140 | 62 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 53 | 26 |
| New patient office or other outpatient visit, 45-59 minutes | 41 | 41 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 37 | 34 |
| Established patient office or other outpatient visit, 20-29 minutes | 35 | 29 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 31 | 28 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 19 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in New Haven, CT | 133 |
| Eliquis (apixaban) Other prescribers in New Haven, CT | 111 |
| Prochlorperazine Maleate Other prescribers in New Haven, CT | 100 |
| Letrozole Other prescribers in New Haven, CT | 80 |
| Dexamethasone Other prescribers in New Haven, CT | 57 |
| Warfarin Sodium Other prescribers in New Haven, CT | 52 |
| Oxycodone Hcl Other prescribers in New Haven, CT | 49 |
| Hydroxyurea Other prescribers in New Haven, CT | 46 |
| Xarelto (rivaroxaban) Other prescribers in New Haven, CT | 44 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in New Haven, CT | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 37 companies reported 227 payments worth $130,346 in total to this clinician.
| Exelixis Inc. | $49,643 |
|---|---|
| Jazz Pharmaceuticals Inc. | $33,367 |
| AstraZeneca Pharmaceuticals LP | $18,609 |
| Pfizer Inc. | $14,556 |
| Incyte Corporation | $5,239 |
| E.r. Squibb & Sons, L.l.c. | $3,792 |
| Janssen Scientific Affairs, LLC | $2,310 |
| Array Biopharma Inc | $763 |
| Compensation for services other than consulting (speaking, faculty) | $54,540 |
|---|---|
| Speaking at a medical education program | $40,115 |
| Travel and Lodging | $16,808 |
| Consulting Fee | $14,660 |
| Food and Beverage | $4,031 |
| Education | $192 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Jazz Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Jazz Pharmaceuticals Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Jazz Pharmaceuticals Inc. Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| AstraZeneca Pharmaceuticals LP Jul 28, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $6,560 |
| Pfizer Inc. May 19, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $4,250 |
| Exelixis Inc. Dec 3, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,955 |
| Exelixis Inc. Dec 19, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,955 |
| Exelixis Inc. Oct 29, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,955 |
| Exelixis Inc. Aug 27, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,955 |
All 98 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Exelixis Inc. Dec 19, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,955 |
| Incyte Corporation Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $1,370 |
| Exelixis Inc. Dec 15, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Durham, NC · in-kind | $515 |
| Exelixis Inc. Dec 12, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Durham, NC · in-kind | $350 |
| Exelixis Inc. Dec 11, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Durham, NC · in-kind | $70.00 |
| Exelixis Inc. Dec 11, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Durham, NC · in-kind | $30.00 |
| Exelixis Inc. Dec 3, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,955 |
| Exelixis Inc. Dec 3, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,695 |
| Exelixis Inc. Nov 24, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind | $229 |
| Exelixis Inc. Nov 24, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind | $225 |
| Exelixis Inc. Nov 24, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind | $225 |
| Exelixis Inc. Nov 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind | $266 |
| Exelixis Inc. Nov 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC | $75.60 |
| Exelixis Inc. Nov 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind | $70.00 |
| Exelixis Inc. Nov 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC | $60.00 |
| Exelixis Inc. Nov 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind | $30.00 |
| Incyte Corporation Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $2,740 |
| Pfizer Inc. Nov 19, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $2,310 |
| Exelixis Inc. Nov 19, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,695 |
| Exelixis Inc. Nov 19, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,695 |
| AstraZeneca Pharmaceuticals LP Nov 10, 2025 | Travel and Lodging IMFINZI · Oncology · travel to Denver, CO Company’s descriptionConsulting Expenses | $75.00 |
| AstraZeneca Pharmaceuticals LP Nov 10, 2025 | Travel and Lodging IMFINZI · Oncology · travel to Denver, CO Company’s descriptionConsulting Expenses | $60.00 |
| AstraZeneca Pharmaceuticals LP Nov 3, 2025 | Consulting Fee IMFINZI · Oncology | $3,690 |
| Incyte Corporation Oct 30, 2025 | Travel and Lodging Zynyz · Oncology · travel to Atlanta, GA | $16.80 |
| Exelixis Inc. Oct 29, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,955 |
| Exelixis Inc. Oct 29, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,814 |
| Exelixis Inc. Oct 27, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX · in-kind | $230 |
| Exelixis Inc. Oct 27, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX · in-kind | $230 |
| AstraZeneca Pharmaceuticals LP Oct 25, 2025 | Travel and Lodging IMFINZI · Oncology · travel to Denver, CO · in-kind Company’s descriptionConsulting Expenses | $323 |
| AstraZeneca Pharmaceuticals LP Oct 24, 2025 | Travel and Lodging IMFINZI · Oncology · travel to Denver, CO · in-kind Company’s descriptionConsulting Expenses | $881 |
| Exelixis Inc. Oct 23, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX · in-kind | $395 |
| Exelixis Inc. Oct 23, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX · in-kind | $70.00 |
| Exelixis Inc. Oct 20, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY · in-kind | $205 |
| Exelixis Inc. Oct 20, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY · in-kind | $205 |
| Pfizer Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $3,275 |
| Exelixis Inc. Oct 17, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY · in-kind | $70.00 |
| Exelixis Inc. Oct 17, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX | $69.93 |
| Exelixis Inc. Oct 17, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY | $60.00 |
| Exelixis Inc. Oct 17, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX | $51.34 |
| Exelixis Inc. Oct 16, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY · in-kind | $411 |
| Exelixis Inc. Oct 6, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind | $622 |
| Pfizer Inc. Oct 6, 2025 | Education TUKYSA · ONCOLOGY · in-kind | $16.01 |
| Jazz Pharmaceuticals Inc. Sep 30, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Newport News, VA · in-kind | $208 |
| Exelixis Inc. Sep 29, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Durham, NC · in-kind | $497 |
| Alexion Pharmaceuticals, Inc. Sep 26, 2025 | Education SOLIRIS · Rare Disease · in-kind Company’s descriptionTextbook | $85.00 |
| Exelixis Inc. Sep 22, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX · in-kind | $542 |
| Jazz Pharmaceuticals Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Jazz Pharmaceuticals Inc. Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Jazz Pharmaceuticals Inc. Sep 3, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Chesapeake, VA · in-kind | $161 |
| Jazz Pharmaceuticals Inc. Aug 28, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Newport News, VA · in-kind | $232 |
| Exelixis Inc. Aug 27, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,955 |
| Incyte Corporation Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $628 |
| Exelixis Inc. Aug 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY · in-kind | $607 |
| Janssen Scientific Affairs, LLC Aug 20, 2025 | Consulting Fee | $1,320 |
| Jazz Pharmaceuticals Inc. Aug 20, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Chesapeake, VA · in-kind | $282 |
| Jazz Pharmaceuticals Inc. Aug 18, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Bloomfield Hills, MI · in-kind | $334 |
| Jazz Pharmaceuticals Inc. Aug 14, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Newport News, VA · in-kind | $697 |
| Exelixis Inc. Aug 11, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind | $216 |
| Exelixis Inc. Aug 11, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind | $205 |
| Exelixis Inc. Aug 10, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind | $381 |
| Exelixis Inc. Aug 10, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind | $91.28 |
| Exelixis Inc. Aug 10, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind | $70.00 |
| Jazz Pharmaceuticals Inc. Aug 9, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Chesapeake, VA · in-kind | $797 |
| Exelixis Inc. Aug 5, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,814 |
| Exelixis Inc. Aug 1, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Charlotte, NC · in-kind | $459 |
| Exelixis Inc. Aug 1, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Charlotte, NC · in-kind | $398 |
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $3,280 |
| Exelixis Inc. Jul 29, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,695 |
| Incyte Corporation Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty) Zynyz · Oncology | $343 |
| AstraZeneca Pharmaceuticals LP Jul 28, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $6,560 |
| Janssen Scientific Affairs, LLC Jul 1, 2025 | Consulting Fee | $990 |
| Exelixis Inc. Jul 1, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind | $521 |
| AstraZeneca Pharmaceuticals LP Jun 25, 2025 | Travel and Lodging travel to Birmingham, AL · in-kind Company’s descriptionSpeaker Expenses | $1,196 |
| Exelixis Inc. Jun 11, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,825 |
| AstraZeneca Pharmaceuticals LP Jun 3, 2025 | Consulting Fee | $2,050 |
| Jazz Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Jazz Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Exelixis Inc. Jun 1, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Atlanta, GA | $60.20 |
| Exelixis Inc. Jun 1, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Atlanta, GA | $3.00 |
| Janssen Biotech, Inc. May 29, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $77.99 |
| Exelixis Inc. May 28, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,695 |
| Pfizer Inc. May 27, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Albany, GA · in-kind | $1,001 |
| Jazz Pharmaceuticals Inc. May 24, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Virginia Beach, VA · in-kind | $105 |
| Jazz Pharmaceuticals Inc. May 24, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Bloomfield Hills, MI · in-kind | $105 |
| Jazz Pharmaceuticals Inc. May 22, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Virginia Beach, VA · in-kind | $109 |
| Jazz Pharmaceuticals Inc. May 22, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Bloomfield Hills, MI · in-kind | $109 |
| Pfizer Inc. May 19, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $4,250 |
| Jazz Pharmaceuticals Inc. May 16, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Virginia Beach, VA · in-kind | $620 |
| Jazz Pharmaceuticals Inc. May 16, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Bloomfield Hills, MI · in-kind | $620 |
| Exelixis Inc. Apr 29, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,695 |
| Pfizer Inc. Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $3,275 |
| Cumberland Pharmaceuticals, Inc. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) SANCUSO · ONCOLOGY | $500 |
| Array Biopharma Inc Mar 6, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $700 |
| Exelixis Inc. Feb 27, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $848 |
| Exelixis Inc. Feb 18, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,825 |
| Pfizer Inc. Feb 17, 2025 | Education BRAFTOVI; MEKTOVI · ONCOLOGY · in-kind | $13.04 |
| Exelixis Inc. Feb 5, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Atlanta, GA | $60.20 |
| E.r. Squibb & Sons, L.l.c. Jan 16, 2025 | Consulting Fee | $3,600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 19 industry-funded studies in 2025, from 8 companies. The companies reported $757,252 in research payments for these studies, mostly to the institutions running them.
- A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
Novartis Pharmaceuticals Corporation - Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-lin…
E.r. Squibb & Sons, L.l.c. - A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Merck Sharp & Dohme LLC - Phase 2/3 BMS-986504+Gemcitabine/Abraxane vs Gemcitabine/Abraxane in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
E.r. Squibb & Sons, L.l.c. - A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Exelixis Inc. - A randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer
AstraZeneca Pharmaceuticals LP - A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Geno…
AstraZeneca Pharmaceuticals LP - A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie Inc. · Recruiting · NCT06568939 - A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Rena…
Merck Sharp & Dohme LLC - Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.